.jpg "Sophia C. Kamran, MD photo")
Massachusetts General Hospital, Harvard Medical School
Sophia C. Kamran, MD, is a Radiation Oncologist with Massachusetts General Hospital, an Assistant Professor of Radiation Oncology at Harvard Medical School, and an Associate Member of the Broad Institute of MIT and Harvard. She is also the Director of Diversity, Equity, and Inclusion in the Department of Radiation Oncology at Massachusetts General Hospital. Dr. Kamran’s clinical interest is in genitourinary cancer care with a focus on harnessing computational/bioinformatics approaches to discover genomic and molecular predictors of response to radiation and characterize mechanisms of resistance. Her goal is to design clinical trials investigating genomically-guided radiation therapy to deliver optimal doses in combination with appropriate systemic therapy for improved outcomes. Dr. Kamran has several professional membership affiliations with organizations such as the American Society for Radiation Oncology (ASTRO), the American Urological Association, the Accreditation Council for Graduate Medical Education, the Radiation Research Society, the American Society for Clinical Oncology (ASCO), the American Board of Radiology, the Massachusetts General Hospital Cancer Center Equity Council, the American Association for Cancer Research, and the Massachusetts Prostate Cancer Coalition. Nationally, she serves on ASTRO's Workforce Diversity Committee, and she was selected as a 2021 ASTRO Leadership Pipeline Program Protégé for her work on diversity, equity, and inclusion efforts. She is the 2024 Co-Chair of the Renal & Rare Tumors Track for the ASCO Genitourinary Cancers Symposium, and was the Organizing Chair for the 2023 Coffey-Holden Prostate Cancer Academy Meeting, sponsored by the Prostate Cancer Foundation. She is also on the NCI P01 Massachusetts General Hospital Internal Steering Committee, serves on the Editorial Board for Clinical Genitourinary Cancer and is a GU Associate Section Editor for Practical Radiation Oncology. Her work has been published in many high-quality journals, including The New England Journal of Medicine, Clinical Cancer Research, JAMA Oncology, European Urology, and others.
Disclosure information not submitted.
Friday, April 28, 2023
8:15 AM – 8:35 AM CST